학술논문

Addiction to Tobacco Smoking and Vaping.
Document Type
Academic Journal
Author
Hernández-Pérez A; Department of Research on Smoking and COPD.; García-Gómez L; Department of Research on Smoking and COPD.; Robles-Hernández R; Department of Research on Smoking and COPD.; Thirión-Romero I; Department of Research on Smoking and COPD.; Osio-Echánove J; Department of Research on Smoking and COPD.; Rodríguez-Llamazares S; Respiratory Intensive Care Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.; Baler R; National Institute on Drug Abuse (NIDA-NIH), Bethesda, Maryland, USA.; Pérez-Padilla R; Department of Research on Smoking and COPD.
Source
Publisher: Permanyer Country of Publication: Mexico NLM ID: 9421552 Publication Model: Print Cited Medium: Internet ISSN: 0034-8376 (Print) Linking ISSN: 00348376 NLM ISO Abbreviation: Rev Invest Clin Subsets: MEDLINE
Subject
Language
English
ISSN
0034-8376
Abstract
The tobacco epidemic has been one of the biggest public health threats, and smoking is one of the world's largest preventable causes of premature death. An estimated 15.4% of all deaths in the world are attributable to tobacco smoking. The present review aims to describe addiction to tobacco smoking and vaping. Tobacco and vaping devices contain nicotine, a highly addictive drug, which explains why smoking is so prevalent and persistent. Electronic cigarettes are a group of novel nicotine or tobacco products that have rapidly gained popularity in recent years. Electronic cigarette devices allow for the use of other drugs, including THC, while the lax regulation may allow for the introduction of toxic compounds that can lead to acute or subacute toxicity, such as the e-cigarette- or vaping-associated lung injury that has been linked to vitamin E acetate. In addition, regular vapers and heated tobacco devices emit toxins, although at lower concentrations than burned tobacco. However, more and more side effects have been identified. No new effective treatment for nicotine addiction has been developed recently, despite its huge adverse impact on overall health and other outcomes. As for the primary line of medications, the last one started in 2006, the varenicline, demonstrating a low interest in developing new medications against smoking, an unacceptable state of affairs, given the huge impact of smoking on morbidity and mortality.
(Copyright: © 2023 Permanyer.)